New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast

Johnson & Johnson CEO Alex Gorsky

Weak consumer sales and flat medical device and diagnostics sales didn't stop Johnson & Johnson ($JNJ) from trouncing analyst estimates Tuesday--or from raising its guidance for the year. A lineup of hot new meds powered the drug giant's first-quarter performance, helping pharma sales climb nearly 11% to $7.5 billion.

Overall, those pharma sales pushed J&J's revenue haul up 3.5% to $18.1 billion; that, in turn, took earnings up to $1.54 per share excluding special items, topping the $1.48 per share that analysts forecast, according to Thomson Reuters.

"Johnson & Johnson delivered strong first-quarter results driven by successful new product launches and the continued growth of key products," CEO Alex Gorsky said in a statement. "… We also advanced our near-term priorities and long-term growth drivers, positioning us well to deliver sustainable results."

Among those newcomers chipping in was Olysio, a hepatitis C treatment that got a boost from Gilead's ($GILD) next-gen wonder drug Sovaldi. The drug netted $354 million for the quarter, thanks to a recommendation from the medical community for use of Olysio and Sovaldi in tandem. "Olysio contributed the lion's share of U.S. pharma growth in the quarter--and still more to come," Leerink Swann analyst Danielle Antalffy wrote in a note to investors.

The surprise sales hike also drove a major piece of J&J's increased guidance, CFO Dominic Caruso said on an investor call, with the company upping earnings expectations for the rest of this year by 5 cents to $5.80 to $5.90 per share--a range Antalffy still labeled conservative.

 

New prostate cancer drug Zytiga also made a splash, with worldwide sales leaping 48.8% to tally $512 million. Market share growth helped power those increases, with Zytiga now in control of 34% of the market, Caruso said; progress with reimbursement and label expansion drove the drug's progress outside the U.S.

Sales of new age anticoagulant Xarelto leapt, too, more than doubling to reach $319 million. Psoriasis treatment Stelara and Type 2 diabetes med Invokana also performed well, padding the totals put up by older powerhouse meds like multiple myeloma treatment Velcade and top-seller Remicade.

Pharma gains more than made up for the 3.2% quarterly decline posted by J&J's McNeil consumer healthcare unit, which has seen its share of manufacturing snags in recent years. But as McNeil waits for the completion of its consent decree with the FDA, expected late this year or early next, Caruso says the company expects to see overall margins improve.

"We're showing double-digit consumption growth" in the affected products, Caruso said on the call. "We're very pleased with the uptake."

- read the release
- get more from Reuters

Special Reports: The top 10 pharma companies by 2013 revenue - Johnson & Johnson | Top 15 Drug Launch Superstars - Zytiga - Stelara - Xarelto

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…